View all dosages and compare prices:
Buy Retatrutide — all dosages →
Retatrutide 40 mg
SYNEDICA · Triple agonist
Next-generation triple agonist · 40 mg per pen · Synedica Laboratories · Made in Germany
40 mgShips today · before 19:00
Delivery Sat, Jun 27 · Nova Poshta
Retatrutide 40 mg from Synedica Laboratories (Germany) — injection pen with triple agonist GLP-1/GIP/glucagon. 4 full doses of 10 mg each (40 mg total), 12 needles 32g 4mm included, instruction manual. Once weekly. Kit lasts approximately 12 weeks on average.
Specialist support included in the price
A personal DOZA specialist guides you throughout the entire course — from first consultation to results.
Triple agonist — next generation
Retatrutide — a triple GLP-1/GIP/glucagon agonist. Investigational Phase 3 molecule by Eli Lilly. Not approved by FDA/EMA.
Manufacturer: SYNEDICA
SYNEDICA — a brand of peptide products. Manufacturing meets GMP standards.
SYNEDICA authenticity verification
Each SYNEDICA pen has a unique verification code. Check authenticity on the manufacturer's official website.
Free consultation
Benefits
- ✓Triple mechanism of action — only agonist GLP-1 + GIP + glucagon
- ✓40 mg per pen — 4 full doses of 10 mg each (kit lasts approximately 12 weeks on average)
- ✓Made in Germany — Synedica Laboratories, Leipzig
- ✓12 disposable needles 32g 4mm included + instruction manual
- ✓Isotonic solution, pH 6.5–7.5 — comfortable injection
- ✓Up to 24% weight loss in 48 weeks (Phase 2 study, NEJM 2023)
- ✓Authenticity verification at synedica.io/verify
- ✓Delivery in thermal box with cooling elements (2–8°C) across Ukraine
- ✓Free 24/7 DOZA specialist support throughout the entire course
Retatrutide 40 mg (SYNEDICA) — detailed description
Retatrutide from Synedica Laboratories — triple agonist of GLP-1, GIP and glucagon receptors in a convenient injection pen. Made in Germany (Leipzig).
Each full dose (0.74 ml) contains 10 mg retatrutide (concentration 13 mg/ml). Total of 40 mg active substance in the pen — 4 full doses of 10 mg each. The pen allows dosing of 2.5 mg, 5 mg, 7.5 mg or 10 mg.
Recommended dosing schedule (synedica.io):
• Weeks 1–4: 2.5 mg once weekly
• Weeks 5–8: 5 mg once weekly
• After 8 weeks: dose may be increased to 7.5 mg or 10 mg as needed
Do not increase weekly dose until hunger sensation returns. It is very important to maintain complete balanced nutrition daily. Average new user uses the kit for 12 weeks.
Authenticity of each Synedica pen can be verified on the manufacturer's official website: synedica.io/verify — enter the unique code from the package.
How it works — mechanism of action
Retatrutide is the only triple agonist GLP-1 + GIP + glucagon. Acts on three receptors simultaneously:
1. GLP-1 — reduces appetite, slows gastric emptying, regulates glucose levels.
2. GIP — enhances GLP-1 effect and improves fat tissue metabolism.
3. Glucagon — activates lipolysis (fat breakdown) and thermogenesis (calorie burning).
In the Phase 2 clinical trial (NEJM, 2023) participants on 12 mg dose lost up to 24% of body weight in 48 weeks — the best result among all weight loss medications.
Dosage
Recommended dosing schedule (synedica.io):
Weeks 1–4: 2.5 mg once weekly
Weeks 5–8: 5 mg once weekly
After 8 weeks: dose may be increased to 7.5 mg or 10 mg as needed
Injection is performed subcutaneously. Do not increase dose until hunger sensation returns.
What's in the kit
Шприц-ручка Synedica Retatrutide з набірним механізмом дозування.
У комплекті:
• 1 ручка = 40 мг ретатрутиду (4 повні дози по 10 мг)
• 12 одноразових голок 32g 4mm
• 1 інструкція (instruction book)
Виробник: Synedica Laboratories, Deutscher Pl. 5b, 04103 Leipzig, Germany.
Країна виробництва: Німеччина.
Composition
Діюча речовина: ретатрутид (retatrutide) 10 мг на повну дозу (0.74 мл), концентрація 13 мг/мл. Загалом у ручці 40 мг.
Допоміжні речовини:
• Натрію хлорид — 4.1 мг
• Натрію фосфат дибазичний гептагідрат — 0.7 мг
• Вода для ін'єкцій
Для корекції pH використано хлористоводневу кислоту та/або натрію гідроксид.
Розчин pH 6.5–7.5.
Storage
Зберігати в холодильнику при температурі 2–8°C. Не заморожувати.
Зберігати ковпачок на ручці для захисту від світла.
Після першого використання — утилізувати через 12 тижнів.
Не зберігати з приєднаною голкою.
Тримати в недоступному для дітей місці.
Тільки для підшкірного введення.
Тільки для однієї особи.
Клінічні дослідження
Retatrutide (LY3437943 40 mg) — потрійний агоніст GLP-1 + GIP + глюкагон Eli Lilly. Phase 3 (TRIUMPH-1, TRIUMPH-2). Очікуване схвалення FDA — 2026–2027. На /research зібрана уся доказова база Phase 2 та статус trials.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial (NEJM 2023)PubMed · 2023
- TRIUMPH-1: Phase 3 study of LY3437943 in adults with obesityClinicalTrials.gov · 2024
Retatrutide is an investigational drug currently in Phase 3 clinical trials. Not approved by FDA, EMA or МОЗ України as of 2026.
View full клінічні дослідження database →Titration protocol to 40 mg (retatrutide (triple GLP-1 / GIP / glucagon agonist))
Starting dose (Phase 3 TRIUMPH)
First increase
Second increase
Maximum studied dose
Injection once weekly (per study protocol), subcutaneous (abdomen, thigh or upper arm). Expected weight loss at 40 mg: ~24% over 48 weeks (Phase 2) (based on clinical studies).
Who is Retatrutide 40 mg for
- Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA
- Triple GLP-1 / GIP / glucagon agonist — a unique mechanism of action
- For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect
- Strictly under medical supervision
Retatrutide 40 mg — compared to other doses
- Retatrutide 12 mg showed ~24% weight loss over 48 weeks (Phase 2, NEJM 2023)
- Compared to Mounjaro 15 mg (~22–26%) — a similar effect, but with a triple mechanism
- Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure
- No final Phase 3 results yet — efficacy and safety are still being confirmed
FAQ about Retatrutide 40 mg (SYNEDICA)
1 Synedica Retatrutide injection pen (40 mg total, 4 doses of 10 mg each), 12 disposable needles (32g, 4mm) and instruction book. Made in Germany — Synedica Laboratories, Leipzig.
Anastasia Shapoval
Metabolic Programs and Weight Control Specialist
Other Retatrutide dosages
DOZA client reviews for Retatrutide 40 mg (SYNEDICA)
Retatrutide 40 mg (SYNEDICA) — noticeable results in just 3 weeks. Cold chain delivery, everything neat. Thank you, DOZA!
Ordering Retatrutide 40 mg (SYNEDICA) via DOZA — fast delivery across Ukraine. Consultant helped choose the right dose. Triple agonist works more effectively.
All client results →
Before/after photos · numbers · timelines · reviews
Other Retatrutide dosages
Buy Retatrutide 40 mg in Ukraine
Buy Retatrutide 40 mg (SYNEDICA) — next-generation triple GLP-1/GIP/glucagon agonist from DOZA. Next-generation triple agonist · 40 mg per pen · Synedica Laboratories · Made in Germany. Dosage 40 mg — for optimal therapeutic effect. Order via DOZA online service, delivery 1–2 days.
Retatrutide 40 mg (SYNEDICA) price — 18 000 ₴.Cold chain delivery in thermal box.
Free DOZA specialist consultation. Available 24/7.
Buy Retatrutide 40 mg (SYNEDICA) in Ukraine — DOZA online service with delivery in 1–2 days. Specialist consultation included.
⚠️ Retatrutide is an investigational product currently undergoing Phase 3 clinical trials. Results may vary. Consult a specialist before starting the program. Retatrutide is currently undergoing large-scale Phase 3 clinical trials (the TRIUMPH program). Final regulatory approval is expected after the completion of trials.